| 产品描述: | A-192621, a chemical probe, is a potent, nonpeptide, orally active and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. The selectivity of A-192621 is 636-fold higher than ETA (IC50 of 4280 nM and Ki of 5600 nM). A-192621 promotes apoptosis in PASMCs. A-192621 alos causes elevation of arterial blood pressure and an elevation in the plasma ET-1 level. |
| 靶点: |
ETB:4.5 nM (IC50); ETB:8.8 nM (Ki); ETA:4280 nM (IC50); ETA:5600 nM (Ki) |
| 体内研究: |
A-192621 (1-100 μM;48 小时;PASMCs) 处理以剂量依赖性方式显著降低 PASMCs 的细胞活力。 A-192621 (1-100 μM;48 小时;PASMCs) 处理可显著增加 PASMCs 中的 caspase-3/7 活性和裂解的 caspase-3 表达。A-192621以剂量依赖的方式诱导细胞凋亡,并通过 Doxorubicin 处理增加细胞对细胞凋亡的易感性。 |
| 参考文献: |
1. Wu-Wong JR, et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Clin Sci (Lond). 2002 Aug;103 Suppl 48:107S-111S. 2. Sakai S, et al. Antagonists to endothelin receptor type B promote apoptosis in human pulmonary arterial smooth muscle cells. Life Sci. 2016 Aug 15;159:116-120. 3. Wessale JL, et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. Clin Sci (Lond). 2002 Aug;103 Suppl 48:112S-117S. |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.79 ml |
8.95 ml |
17.9 ml |
| 5 mM |
0.358 ml |
1.79 ml |
3.58 ml |
| 10 mM |
0.179 ml |
0.895 ml |
1.79 ml |
| 50 mM |
0.036 ml |
0.179 ml |
0.358 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |